Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26746322 | 1.00 | HSD11B1 (0.39) | HSD11B1KDM4ETDP1GPR119KMT2A | |
| SCHEMBL29316776 | 0.86 | HRH3 (0.42) | — | |
| SCHEMBL29316784 | 0.86 | HRH3 (0.42) | — | |
| SCHEMBL29330632 | 0.79 | HSD11B1 (0.64) | HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL26754604 | 0.79 | HSD11B1 (0.64) | HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL26746721 | 0.78 | HSD11B1 (0.46) | HSD11B1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL29330604 | 0.75 | HRH3 (0.38) | — | |
| SCHEMBL21733011 | 0.71 | HSD11B1 (0.41) | HSD11B1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL12448266 | 0.70 | EPHX1 (0.39) | GPR119KMT2AMEN1 | |
| SCHEMBL26745442 | 0.69 | HSD11B1 (0.32) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HSD11B1 2940/4885KDM4E 1040/4885TDP1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.